International Review of Ophthalmology ›› 2022, Vol. 46 ›› Issue (6): 565-571.doi: 10.3760/ cma.j.issn.1673-5803.2022.06.016

Previous Articles     Next Articles

Advances in basic research on gene therapy of corneal diseases mediated by adeno-associated virus

Wang Feng1, Lai Jiangfeng1, Shao Yi2   

  1. 1Department of Ophthalmology, Meizhou Pepole’s Hospital, Meizhou, Guangdong 514000, China; 2Department of Ophthalmology, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China
  • Received:2022-02-05 Online:2022-12-22 Published:2022-12-22
  • Contact: Shao Yi, Email: freebee99 @163.com
  • Supported by:
    National Natural Science Foundation (82160195); Central Government Guides Local Science and Technology Development Foundation (20211ZDG02003); Key Research Foundation of Jiangxi Province (20181BBG70004, 20203BBG73059); Research and cultivation project of Guangdong Meizhou People's Hospital (PY-C2021060)

Abstract: Adeno Associated Virus (AAV) mediated gene therapy targets genetic material to corneal diseases through gene enhancement, gene deletion and/or gene editing. The accessibility of targeted drug delivery and high transduction efficiency enable AAV mediated gene therapy to effectively treat corneal diseases, including inhibiting corneal neovascularization and improving corneal opacity related to mucopolysaccharosis. To promote the healing of corneal mechanical and chemical injuries, treat infectious keratitis, and effectively transfect corneal endothelial cells to treat congenital hereditary corneal endothelial dystrophy, it provide a new way to treat corneal diseases. (Int Rev Ophthalmol, 2022, 46: 565-571)

Key words: adeno-associated viruses, cornea, corneal diseases,  , gene therapy